Biogen Pharmachem Industries Ltd — Others, 25-08-2025: Others

Biogen Pharmachem has submitted its Annual Report for FY2024-25 and announced its 30th Annual General Meeting. The company reported an operating income of approximately Rs 1.20 Cr, resulting in a net loss of about Rs 0.29 Cr for the year. No dividend was declared. Among the key proposals for shareholder approval are the re-appointment of statutory auditors, the appointment of Mr. Kelash Bunkar as Whole-Time Director & CFO on nil remuneration, and Mr. Aman Patel as an Independent Director. Shareholders will also consider enhancing borrowing limits by Rs 100 Cr and investment/loan limits by Rs 100 Cr to support future business growth. The company received Rs 35.70 Cr from convertible warrants.